Literature DB >> 17561470

Mycobacterium tuberculosis bacteremia in HIV-negative patients.

Yu-Shin Chiu1, Jann-Tay Wang, Shan-Chwen Chang, Jih-Luh Tang, Shih-Chi Ku, Chien-Ching Hung, Po-Ren Hsueh, Yee-Chun Chen.   

Abstract

BACKGROUND/
PURPOSE: Limited information exists about the epidemiologic characteristics of HIV-negative patients with Mycobacterium tuberculosis bacteremia (MTB).
METHODS: We retrospectively surveyed tuberculosis (TB) cases reported at National Taiwan University Hospital between 1997 and 2003. Demographic data, underlying diseases or conditions, clinical, microbiologic and radiologic findings and therapy were collected. Long-term outcome was evaluated at 1 year after initiation of anti-TB agents.
RESULTS: During the study period the incidence of MTB bacteremia in HIV-negative patients and HIV-positive patients were 0.024 and 6.2 per 1000 discharges, respectively (p<0.01). All 11 HIV-negative patients were males and eight (73%) were more than 50 years old. The most common underlying diseases/conditions were immunosuppressive therapy (64%) and heart disease (55%). Fever (80%), lymphopenia (75%) and pulmonary symptoms (58%) were the most common presentations. Ten patients were septic, two had septic shock and two had acute respiratory distress syndrome on admission. The median interval between admission and initiation of therapy for those who were cured was 6 days. Six (55%) died of TB and/or their underlying diseases. Of the six patients who died, the median survival after collection of positive blood culture was 19 days for three treated patients and 7 days for three untreated patients (p=0.01).
CONCLUSION: This case series demonstrates the wide spectrum of the initial presentation of HIV-negative patients with MTB bacteremia. The case fatality rate was high and was likely due to immunocompromised status and no anti-TB treatment prior to death. A high index of suspicion for TB and blood culture for MTB provides an additional simple and noninvasive diagnostic method to detect disseminated TB in endemic areas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561470     DOI: 10.1016/S0929-6646(09)60320-X

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

1.  Mycobacterium tuberculosis bacteremia in a human immunodeficiency virus-negative patient with liver cirrhosis: A case report.

Authors:  Zhe-Zhe Lin; Dan Chen; Sai Liu; Jian-Hua Yu; Shou-Rong Liu; Ming-Li Zhu
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

2.  18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort?

Authors:  Ruoh-Fang Yen; Ke-Cheng Chen; Jang-Ming Lee; Yeun-Chung Chang; Jane Wang; Mei-Fang Cheng; Yen-Wen Wu; Yung-Chie Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-19       Impact factor: 9.236

3.  Disseminated tuberculosis presenting with polymorphonuclear effusion and septic shock in an HIV-seropositive patient: a case report.

Authors:  Olivier Nancoz; Omar Kherad; Etienne Perrin; Christophe Hsu; Johannes Alexander Lobrinus; Mathieu Nendaz
Journal:  J Med Case Rep       Date:  2010-05-26

4.  Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects.

Authors:  Michelle B Ryndak; Krishna K Singh; Zhengyu Peng; Susan Zolla-Pazner; Hualin Li; Lu Meng; Suman Laal
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

5.  Bacteremia tuberculosis among HIV-negative children in China.

Authors:  Ping Chu; Jin Shi; Fang Dong; Hui Yang; Shunying Zhao; Gang Liu; Huyong Zheng; Jinrong Liu; Huimin Li; Jie Lu
Journal:  Pediatr Investig       Date:  2022-09-05

6.  Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center.

Authors:  Karla Maria Tamez-Torres; Pedro Torres-Gonzalez; Miguel E Cervera-Hernandez; Barbara Chavez-Mazari; Corazon de Jesus Barrientos-Flores; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-Leon; Jose Sifuentes-Osornio
Journal:  Braz J Infect Dis       Date:  2018-10-30       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.